Ken Kobayashi
Chief Tech/Sci/R&D Officer bei PYXIS ONCOLOGY, INC.
Profil
Ken Kobayashi is currently the Chief Medical Officer at Pyxis Oncology, Inc. Prior to this, he held positions as VP-Early Oncology Development & Clinical Research at Pfizer Inc. and Senior Vice President-Clinical Development at Kinnate Biopharma, Inc. He received his undergraduate degree from the University of Washington and his doctorate from the Feinberg School of Medicine.
Aktive Positionen von Ken Kobayashi
| Unternehmen | Position | Beginn |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 27.11.2023 |
Ehemalige bekannte Positionen von Ken Kobayashi
| Unternehmen | Position | Ende |
|---|---|---|
| KINNATE BIOPHARMA INC. | Chief Tech/Sci/R&D Officer | 02.03.2023 |
| PFIZER, INC. | Corporate Officer/Principal | - |
Ausbildung von Ken Kobayashi
| University of Washington | Undergraduate Degree |
| Feinberg School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| PYXIS ONCOLOGY, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Kinnate Biopharma, Inc.
 Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
